Centre examining all possible storage facilities for Pfizer's Covid vaccine

The Union Health Ministry said that the central government is examining all possibilities to extend cold chain facilities in case Pfizer's Covid-19 vaccine needs to be procured

Vaccine
Representative photo of a vaccine
ANI General News
2 min read Last Updated : Nov 18 2020 | 6:33 AM IST

 

New Delhi [India], November 18 (ANI): The Union Health Ministry on Tuesday said that the central government is examining all possibilities to extend cold chain facilities in case Pfizer's COVID-19 vaccine needs to be procured.

Responding to a query on vaccine storage at low temperature, Dr VK Paul, NITI Aayog member (Health) said it would be a huge challenge for any country to maintain cold chain facility at a lower temperature of -70 degree or -80 degree celsius and scale-up vaccine procurement.

"However, knowing all the circumstances, we are examining how to scale up vaccine storage facilities."

"We are keeping a close watch on the development of these vaccines and we are also aware of the fact that we won't be able to get a large number of doses of this vaccine required for our population. In case, union government procures it, all necessary arrangements will be made parallelly," said Dr Paul at a media briefing on COVID-19 update in India.

The NITI Aayog member further said that there are five COVID-19 vaccine candidates under various stages of clinical trials in India of which two are in the third phase.

"India is one of the countries which is showing good progress in COVID-19 vaccine trials. Serum Oxford vaccine is in the completion of the phase 3 trials and Bharat Biotech's COVID-19 vaccine's candidate has begun phase 3 trials and the results for phase 2 trials can be announced any time. Zydus Cadila has completed phase 2 trials" Dr Paul said.

"The Russian vaccine in collaboration with Dr Reddy's Laboratories will begin phase 2 and 3 clinical trials soon while Biological E coronavirus vaccine's early phase 1 and 2 clinical trials have been launched," he added.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus VaccineIndiaPfizerCoronavirus TestsIndian healthcare systemHealth crisisHealth Ministry

First Published: Nov 18 2020 | 12:15 AM IST

Next Story